Fastest-growing Biotech Companies in Massachusetts
Reporter: Aviva Lev-Ari, PhD, RN
- Alnylam Pharmaceuticals, Cambridge, John Maraganore, CEO
$5.2 Billion Marker cap, $41 Million in 2015 revenue
- Genocea Biosciences, Cambridge, Chip Clark, CEO
$127 Million Market cap, $670,000 in 2015 revenue
- ArQule, Burlington, Paolo Pucci, CEO
$109 Million Market cap, $11 Million in 2015 revenue
- Foundation Medicine, Cambridge, Michael Pellini, CEO
$ 604 Million Market cap, $ 93 Million in 2015 revenue
- bluebird bio, Cambridge, Nick Leschly, CEO
$ 1.6 Billion Market cap, $ 14 Million in 2015 revenue
- Sage Therapeutics, Cambridge, Jeffrey Jonas, CEO
$ 1.04 Billion Market cap, $ O Million in 2015 revenue
- Amag Pharmaceuticals, Waltham, Bill Heiden, CEO
$ 754 Million Market cap, $ 418 Million in 2015 revenue
- Tesaro, Waltham, Leon Moulder, CEO, Co-Founder
$ 1.8 Billion Market cap, $ 317,000 Million in 2015 revenue
- Radius Health, Waltham, Bob Ward, President and CEO
$ 1.43 Billion Market cap, $ 0 Million in 2015 revenue
investigational drug abaloparatide for the reduction of fracture risk in postmenopausal osteoporosis
All data is according to the latest federal filings from the companies as compiled by Bloomberg.
Here are the 9 fastest-growing biotech firms in the Bay State
Mar 22, 2016, 11:36am EDT Updated Mar 22, 2016, 11:53am EDT
Click through the attached slideshow to see what other companies made the list.
SOURCE
The list includes a few of the area’s largest firms — including Alnylam Pharmaceuticals (Nasdaq: ALNY) and Amag Pharmaceuticals (Nasdaq: AMAG) — and mostly consists of those with little or no revenue. In fact, three of the companies had no revenue in 2015 at all.
At the top of the list is Radius Health (Nasdaq: RDUS), a company which is planning to submit its application for its first-ever drug in coming days, which grew from just 25 employees as of Dec. 31, 2014 to 73 employees a year later (the Waltham-based company has more than 100 employees today). Most of them (48) are in research and development, while 27 are engaged in administration, business development and finance.
“Since our initial IPO in 2014, we have grown exponentially as we evolve from a development stage biopharmaceutical company to a commercial organization,” CEO Robert Ward said in an email. ”We have established a robust and influential presence in Massachusetts, and are looking forward to continuing the momentum with the planned submission of our New Drug Application to the U.S. Food and Drug Administration at the end of this month for our investigational drug abaloparatide for the reduction of fracture risk in postmenopausal osteoporosis.”
The second slot on the list is Tesaro (Nasdaq: TSRO), also in Waltham, which employed 286 people as of the end of last year.
All data is according to the latest federal filings from the companies as compiled by Bloomberg. Click through the attached slideshow to see what other companies made the list.
SOURCE
Leave a Reply